Stocks股票 / Health Care / WST
WST US listed · USD美股 · 美元
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems.西氏医药服务公司是一家注射用药品包装和给药系统的设计商和制造商。
Company news公司新闻
The latest reporting最新报道
One story, with the reporting behind it.将同一事件汇总,保留各来源报道。
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-10-26Earnings财务业绩
Estimates being cut预期下调
Beat expectations 4 quarters in a row连续 4 季度超预期
Post-earnings drift: +4.7% (20d)财报后漂移:+4.7%(20日)
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 17.4%
Valuation估值
Expensive vs sector相对行业偏贵| Multiple指标 | WST | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(历史) | 57.19x | 31.50 | |
| P/B市净率 | 8.89x | 3.57 | |
| P/S市销率 | 9.18x | 3.19 | |
| Earnings yield盈利收益率 | 1.75% | 2.37 | |
| FCF yield自由现金流收益率 | 1.66% | 3.88 | |
| Shareholder yield股东收益率 | 0.69% | 1.83 | |
| EV/EBITDA企业价值/EBITDA | 36.55x | 19.32 | |
| P/FCF市值/自由现金流 | 60.21x | 23.56 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Debt coming due到期债务
FY2025 10-KIn the 12-month bucket following fiscal period end 2025-12-31, it reported $0 due — about 0% of its disclosed principal.在财年期末 2025-12-31 之后12个月的区间内,已披露到期本金为 $0,约占其披露本金的 0%。
All maturity buckets are measured from fiscal period end 2025-12-31, not from today.所有到期区间均从财年期末 2025-12-31 起算,而非从今天起算。
Cash reported at 2025-12-31: $791300000.截至 2025-12-31 披露的现金:$791300000。 Operating cash flow exceeded or equaled equipment spending over 2025-01-01 to 2025-12-31; no cash burn to measure.在 2025-01-01 至 2025-12-31 期间,经营现金流不低于设备支出,无可衡量的现金消耗。
Capital-need coverage is partial; incomplete or incompatible filing inputs are not combined.资本需求覆盖信息不完整;不会合并不完整或不兼容的报告数据。
Any available cash-flow scenario is context only. Missing or incompatible inputs are not replaced with zero or a financing forecast.可用现金流情景仅供参考;缺失或不兼容的输入不以零值或融资预测替代。
Sources and cash-flow calculation来源与现金流计算
Figures are XBRL facts from one filing — no two years are mixed. Filing数据取自同一份文件中的 XBRL 事实,不跨文件拼接。文件
0000105770-26-000010, period ending报告期截至 2025-12-31, unit单位 USD.
Cache acquired缓存获取时间: 2026-10-05T09:40:54.711018+00:00.
2/6 buckets reported.个区间有披露。
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwoLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive— period_mismatch
Annual period年度区间 2025-01-01 — 2025-12-31 · USD · 10-K · 0000105770-26-000010 · Filed提交日期 2026-02-17.
Cache acquired缓存获取时间: 2026-10-05T09:40:54.711018+00:00 · Evaluated as of评估截至 2026-10-26.
- Reported operating cash flow已披露经营活动现金流: $754800000
- Reported equipment spending (capex outflow)已披露设备支出(资本开支流出): $285900000
- Derived free cash flow (operating cash flow minus capex)计算所得自由现金流(经营现金流减资本开支): $468900000
Cash is the reported balance at period end. The runway scenario holds this annual cash-flow pace constant and excludes debt payments, restricted-cash adjustments and future financing.现金为期末已披露余额。现金跑道情景假设本年度现金流速度保持不变,不包括债务偿还、受限现金调整与未来融资。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Options positioning期权持仓
as of last close截至上一收盘Market makers are net long gamma — price pinned near current level做市商净持有正伽玛,价格倾向于在当前水平附近震荡
Flow:资金流向: $0M premium traded; 0% 0DTE; 1 fresh positions; P/C 0.44; ~leans bearish/hedging (direction approx)成交权利金 $0M;0DTE占0%;1个新建仓;看跌看涨比 0.44;≈偏看跌/对冲(方向近似)
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向: -$6.6M net (0 buyers, 2 sellers)-$6.6M 净值(0 买家,2 卖家)
Concentrated ownership集中持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | As of截至 |
|---|---|---|---|---|
| Gates Foundation Trust | D | Holding持有 | 0.5% | 2026-06-30 |
| Viking Global (Halvorsen) | B | exitexit | 0.0% | 2026-06-30 |
Signal history信号历史
engine events引擎事件Company profile公司档案
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems.西氏医药服务公司是一家注射用药品包装和给药系统的设计商和制造商。
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(静态) | 57.2× | 31.5× | 20% |
| Price / Book市净率 | 8.9× | 3.6× | 15% |
| Price / Sales市销率 | 9.2× | 3.2× | 15% |
| EV / EBITDAEV/EBITDA | 36.5× | 19.3× | 17% |
| Earnings yield盈利收益率 | 1.8% | 2.4% | 40% |
| Free-cash-flow yield自由现金流收益率 | 2.7% | 5.2% | 23% |
| Shareholder yield股东综合回报率 | 0.7% | 1.8% | 28% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | +2.1% | -0.4% |
| 1 Month近1月 | +4.3% | -1.0% |
| 3 Months近3月 | +19.6% | +3.1% |
| 6 Months近6月 | +28.2% | +7.0% |
| Year to date年初至今 | +42.1% | +12.1% |
| 1 Year近1年 | +27.9% | +14.4% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $2.1B | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| EPS每股收益 | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Free cash flow自由现金流 | $298M | $331M | $439M | $414M | $276M | $469M |
| Gross margin毛利率 | 35.8% | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| Net margin净利率 | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| FCF margin自由现金流利润率 | 13.9% | 11.7% | 15.2% | 14.1% | 9.6% | 15.3% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: accruals near the peer median盈利质量:应计利润接近同业中位
- Working capital: working capital roughly in line with sales营运资本:营运资本与销售大致同步
- Pricing power: gross margin +0.1pts over 6 years定价能力:毛利率 6 年上升 0.1 个百分点
- Capital discipline: investment near the peer median资本纪律:投资力度接近同业中位
- Balance sheet: Altman Z 18.46 — safe zone资产负债表:Altman Z 18.46——安全区
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $2.37 | $2.08 | +13.9% |
| Mar 2026 | $2.13 | $1.68 | +26.8% |
| Dec 2025 | $2.04 | $1.83 | +11.5% |
| Sep 2025 | $1.96 | $1.67 | +17.4% |
Estimate revisions预期修正
Dealer positioning map做市商持仓地图
Volatility pricing波动率定价
Tracked funds holding it跟踪基金持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | Position市值 |
|---|---|---|---|---|
| Gates Foundation Trust | D | Holding持有 | 0.5% | $160M |
| Viking Global (Halvorsen) | B | Exited清仓 | 0.0% | $105M |